ROCKVILLE, Md., Sept. 16, 2014 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing
novel anti-infective biologic and drug programs targeting specific
pathogens that cause serious infections and
diseases, announced today the completion of the
Company's Investor Day in New York
which highlighted its irritable bowel syndrome (IBS) program,
including its novel, oral product SYN-010, targeting
constipation-predominant IBS (C-IBS).
In the keynote presentation, Mark
Pimentel, MD, Director of the GI Motility Program and
Laboratory at Cedars-Sinai Medical Center and Chairman of Synthetic
Biologics' C-IBS Clinical Advisory Board, described SYN-010 as
belonging to the pharmaceutical class of statins, which
have mainly been prescribed for managing cholesterol levels.
SYN-010 is a proprietary modified release formulation of a
classical statin that is optimal for reducing methane-production by
certain microorganisms (Methanobrevibacter smithii) in the
gut while avoiding systemic drug absorption. Methane produced by
these organisms is perceived as the underlying cause of bloating,
pain and constipation associated with C-IBS, and may contribute to
the pathology of other diseases. SYN-010 is intended to treat the
"core" cause of C-IBS, not just the symptoms.
Presentations at the Company's event included an overview of the
anticipated 505(b)(2) regulatory pathway for SYN-010 to reduce the
impact of methane producing organisms on C-IBS and details on the
extensive portfolio of granted use patents and pending applications
for SYN-010 licensed by Cedars-Sinai to the Company.
Additional worldwide patent filings covering composition of
matter claims, which were recently filed by Cedars-Sinai and
licensed to the Company, could extend patent protection of SYN-010
to 2035.
Dr. Pimentel's talk discussed his work that led to the discovery
of SYN-010, including the association between the overproduction of
methane gas by microorganisms in the gut and conditions such as
C-IBS, and possibly other common morbidities such as obesity and
Type-2 diabetes, as well as details on SYN-010's molecular
composition which classifies it as a statin.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology
company focused on the development of novel anti-infective biologic
and drug candidates targeting specific pathogens that cause serious
infections and diseases. The Company is developing an oral biologic
to protect the gastrointestinal microflora from the effects of IV
antibiotics for the prevention of Clostridium difficile (C.
difficile) infection, an oral treatment to reduce the impact of
methane producing organisms on constipation-predominant irritable
bowel syndrome (C-IBS), a series of monoclonal antibodies for the
treatment of Pertussis and Acinetobacter infections, and a
biologic targeted at the prevention and treatment of a root cause
of a subset of IBS. In addition, the Company is developing an oral
estriol drug for the treatment of relapsing-remitting multiple
sclerosis (MS) and cognitive dysfunction in MS. For more
information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
This release includes forward-looking statements on Synthetic
Biologics' current expectations and projections about future
events. In some cases forward-looking statements can be identified
by terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions. These statements are based
upon current beliefs, expectations and assumptions and are subject
to a number of risks and uncertainties, many of which are difficult
to predict and include statements regarding, extension of patent
protection to 2035 and intended impact of SYN-010. The
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from those set
forth or implied by any forward-looking statements. Important
factors that could cause actual results to differ materially from
those reflected in Synthetic Biologics' forward-looking statements
include, among others, our failure to initiate trials within
the anticipated time frame, the ability to successfully and
obtain desired results and other factors described in
Synthetic Biologics' report on Form 10-K for the year ended
December 31, 2013 and any other
filings with the SEC. The information in this release is provided
only as of the date of this release, and Synthetic Biologics
undertakes no obligation to update any forward-looking statements
contained in this release on account of new information, future
events, or otherwise, except as required by law.
Logo -
http://photos.prnewswire.com/prnh/20130522/MM19465LOGO
SOURCE Synthetic Biologics, Inc.